Richardson, P. G., Schjesvold, F., Weisel, K., Moreau, P., Anderson, L. D., White, D., Rodriguez‐Otero, P., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Beksac, M., Oriol, A., Lindsay, J., Liberati, A. M., Galli, M., Robak, P., Larocca, A., Yagci, M., Vural, F., Kanate, A. S., Jiang, R., Grote, L., Peluso, T., & Dimopoulos, M. (2022). pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. European journal of haematology, 108, 73–83. http://access.bl.uk/ark:/81055/vdc_100147204180.0x000042